```html

Zollinger‑Ellison Syndrome (Duodenal Ulcer Disease)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare, hormone‑producing tumor (gastrinoma) that causes the stomach to secrete excessive amounts of gastric acid. The resulting hyperacidity leads to recurrent peptic ulcers, most commonly in the duodenum, but also in the jejunum, stomach, and even the esophagus. ZES accounts for less than 1 % of all duodenal ulcer disease, yet it is responsible for a disproportionate amount of severe, treatment‑resistant ulcers.

• Typical age of onset: 30–60 years, but cases are reported in children and the elderly.
• Gender: Slight male predominance (≈55 % men).
• Prevalence: Approximately 1–3 cases per million people worldwide (Mayo Clinic, 2023).
• Association with genetic syndromes: 20‑30 % of patients have Multiple Endocrine Neoplasia type 1 (MEN‑1), an inherited condition that predisposes to tumors of the pancreas, parathyroid, and pituitary glands.

Symptoms

Because the excess acid can damage any part of the upper gastrointestinal (GI) tract, symptoms are often varied and may mimic other ulcer‑related conditions. Common and less common manifestations include:

Gastro‑intestinal symptoms

• Recurrent abdominal pain: Usually epigastric, worsens 1–3 hours after meals (when acid peaks).
• Diarrhea: Occurs in up to 70 % of patients; can be watery, fatty (steatorrhea), or alternating with constipation.
• Heartburn / Acid reflux: Persistent burning sensation, often unresponsive to standard antacids.
• Nausea & vomiting: May be caused by ulcer‑induced gastric outlet obstruction.
• Gastrointestinal bleeding: Melena or hematochezia from ulcer erosion.
• Weight loss: Secondary to malabsorption and chronic pain.

Systemic signs

• Fatigue: From chronic anemia or malnutrition.
• Electrolyte disturbances: Particularly low potassium and magnesium due to chronic diarrhea.
• Steatorrhea & Vitamin deficiencies: Fat‑soluble vitamins (A, D, E, K) may be poorly absorbed.

Signs specific to MEN‑1 (if present)

• Hyperparathyroidism (high calcium levels)
• Pituitary adenomas (headaches, visual changes)

Causes and Risk Factors

ZES results from a gastrin‑secreting neuroendocrine tumor, most often located in the “gastrinoma triangle” – the duodenum, pancreas, or the tissue surrounding the duodenum. The exact cause of sporadic gastrinomas is unknown, but several risk factors have been identified:

• Genetic predisposition: Inherited MEN‑1 mutation (autosomal dominant) increases risk 10‑fold.
• Family history of neuroendocrine tumors: Even without MEN‑1, a first‑degree relative with a gastrinoma raises suspicion.
• Chronic H. pylori infection: While H. pylori is a primary cause of typical duodenal ulcers, it does not cause ZES; however, co‑infection can exacerbate ulcer severity.
• Smoking: Increases the likelihood of developing neuroendocrine tumors.
• Age & gender: Middle‑aged adults, especially men, are more frequently diagnosed.

Diagnosis

Because ZES mimics ordinary ulcer disease, a high index of suspicion is required, especially when ulcers are multiple, refractory to therapy, or located distal to the duodenum.

1. Laboratory tests

• Fasting serum gastrin: Levels >1,000 pg/mL (normal <100 pg/mL) are highly suggestive.
• Secretin stimulation test: Administration of secretin normally lowers gastrin; in ZES, gastrin paradoxically rises >120 pg/mL, confirming a gastrinoma (NIH, 2022).
• Stool studies: Fecal fat quantification if steatorrhea is suspected.
• Electrolytes & CBC: Evaluate for anemia, hypokalemia, and metabolic alkalosis.

2. Imaging studies

• Endoscopic Ultrasound (EUS): Highly sensitive (≈85 %) for small duodenal or pancreatic gastrinomas.
• Multiphasic CT or MRI: Detects larger primary tumors and liver metastases.
• Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT: Gold standard for locating neuroendocrine tumors and assessing metastatic spread.
• Upper endoscopy (EGD): Visualizes ulcer burden, biopsies to rule out H. pylori or malignancy.

3. Histopathology

If a lesion is resected, microscopic examination confirms a neuroendocrine tumor by staining positive for chromogranin A and synaptophysin.

Treatment Options

Management centers on two goals: control gastric acid hypersecretion and eradicate or control the gastrinoma.

Acid‑control medications

• Proton‑pump inhibitors (PPIs): High‑dose omeprazole (40–80 mg daily) or equivalent; often required indefinitely.
• H2‑receptor antagonists: May be added for breakthrough symptoms, but PPIs remain primary therapy.

Surgical treatment

• Curative resection: Preferred for localized tumors (<2 cm) without metastasis; includes enucleation or pancreaticoduodenectomy.
• Debulking surgery: Reduces tumor burden in metastatic disease to improve symptom control.
• Liver-directed therapies: Radiofrequency ablation or hepatic artery embolization for liver metastases.

Medical therapy for unresectable or metastatic disease

• Somatostatin analogues (octreotide, lanreotide): Inhibit gastrin release and may shrink tumors.
• Targeted agents: Everolimus or sunitinib for progressive neuroendocrine tumors (based on NCCN guidelines).
• Chemotherapy: Reserved for high‑grade or rapidly progressive disease; regimens include streptozocin‑based combinations.

Lifestyle and supportive care

• Small, frequent meals to lessen gastric load.
• Avoid NSAIDs, aspirin, and other ulcer‑aggravating drugs.
• Stop smoking and limit alcohol.
• Supplement fat‑soluble vitamins (A, D, E, K) if malabsorption is documented.

Living with Zollinger‑Ellison Syndrome (duodenal ulcer disease)

Long‑term management is a team effort involving gastroenterologists, endocrine surgeons, dietitians, and sometimes genetic counselors.

Daily management tips

1. Medication adherence: Take PPIs exactly as prescribed; missing a dose can precipitate severe pain.
2. Track symptoms: Keep a diary of pain episodes, stool patterns, and any bleeding.
3. Nutrition: Emphasize a balanced diet rich in lean protein and complex carbohydrates; consider low‑fat meals if steatorrhea persists.
4. Hydration & electrolytes: Replace fluids lost through diarrhea; oral rehydration solutions containing potassium and magnesium are helpful.
5. Regular follow‑up: Serum gastrin and imaging every 6–12 months to monitor for recurrence or metastasis.
6. Genetic counseling: If MEN‑1 is diagnosed, screen family members and arrange periodic testing for related endocrine tumors.

Prevention

Because most gastrinomas are sporadic, primary prevention is limited. However, patients can lower the risk of ulcer complications and possibly tumor progression by:

• Eradicating Helicobacter pylori if present (triple therapy).
• Avoiding chronic use of NSAIDs or corticosteroids.
• Maintaining a healthy weight and quitting tobacco.
• Adhering to prescribed acid‑suppression therapy to prevent ulcer formation.

Complications

If untreated or poorly controlled, ZES can lead to serious health problems:

• Perforated ulcer: Can cause acute abdomen and peritonitis.
• Gastrointestinal bleeding: May require transfusion or endoscopic intervention.
• Obstruction: Due to ulcer scarring or tumor mass effect.
• Metastatic disease: Liver is the most common site; leads to hepatic dysfunction.
• Malnutrition: Chronic diarrhea and malabsorption cause weight loss, anemia, and osteoporosis.
• Secondary cancers: MEN‑1 patients have higher risk of pancreatic neuroendocrine carcinoma and pituitary tumors.

When to Seek Emergency Care

---

Sources: Mayo Clinic. “Zollinger‑Ellison syndrome.” 2023; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Gastrinoma (Zollinger‑Ellison syndrome).” 2022; American College of Gastroenterology (ACG) Clinical Guideline, 2021; National Comprehensive Cancer Network (NCCN) Neuroendocrine Tumor Guidelines, 2023; World Health Organization (WHO) Classification of Tumours of the Digestive System, 2022.

```